Anti-inflammatory medications for gout: what helps during an attack and how to choose treatment

Gout isn't simply a high uric acid level in the blood test; it's an inflammatory disease in which monosodium urate crystals trigger a very painful arthritis attack. Therefore, during an attack, a person needs not medications that lower uric acid levels "for the future," but rather agents that quickly suppress inflammation, reduce pain, and restore joint mobility. Current recommendations distinguish between these two objectives: stopping an attack and long-term disease control. [1]

Currently, major clinical guidelines agree on one key point: nonsteroidal anti-inflammatory drugs, colchicine, and glucocorticosteroids remain the first-line treatments for acute gout attacks. The UK's National Institute for Health and Care Excellence recommends offering one of these options as the first line, taking into account comorbidities, existing medications, and patient preferences. [2]

This is also important because patients often seek the "strongest" drug, although in practice the question is posed differently: which anti-inflammatory drug will provide sufficient effect for this particular person and not carry a disproportionately high risk of complications. In cases of chronic kidney disease, peptic ulcer disease, diabetes, anticoagulant use, advanced age, and multiple drug therapy, the choice may change significantly. [3]

A separate problem is that many perceive a gout attack as a brief episode of pain that must simply be "endured." However, modern reviews emphasize that the goal of treatment is not just to wait it out, but to quickly reduce inflammation and pain. The more appropriate the medication chosen and the earlier treatment is started, the easier the attack usually is and the lower the risk of prolonged inflammation and repeated emergency room visits. [4]

Finally, it's important to differentiate between two concepts. Anti-inflammatory medications for gout treat the attack itself, but do not remove uric acid crystals from the tissues. Urate-lowering medications are used for long-term disease control, while anti-inflammatory drugs can be used either to relieve an exacerbation or temporarily to prevent attacks at the beginning of such therapy. [5]

Table 1. What anti-inflammatory drugs do for gout

Task	What do the drugs do?
Acute attack	Reduces inflammation, pain, swelling, and joint sensitivity
Initiation of urate-lowering therapy	May temporarily prevent provocative attacks
Long-term dissolution of crystals	They do not provide it themselves
Choice of drug	Depends on concomitant diseases, interactions and preferences
Main groups	Nonsteroidal anti-inflammatory drugs, colchicine, glucocorticosteroids

Based on guidelines from the UK National Institute for Health and Care Excellence and the American College of Rheumatology.[6]

What groups of drugs are used most often?

Current reviews and guidelines indicate that nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticosteroids, and colchicine generally have comparable efficacy in controlling attack symptoms, and the choice between them is usually determined not by drug strength but by the clinical situation. A 2025 review explicitly states that these three groups demonstrated similar efficacy in treating attacks, but differ primarily in their adverse effect profiles, associated limitations, and availability. [7]

Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the classic first-line treatment option. They reduce prostaglandin synthesis, thereby reducing inflammation and pain. Reviews of gout list indomethacin, naproxen, and selective cyclooxygenase-2 inhibitors (COX-2) such as celecoxib as examples of commonly used agents, but none is universally recognized as the best choice for all patients. [8]

Colchicine occupies a special place. It is not a universal pain reliever, but an anti-inflammatory drug with its own mechanism of action against crystalline inflammation. The American College of Rheumatology emphasizes that if colchicine is chosen, preference should be given to low doses rather than older, higher-dose regimens, because, while similarly effective, low doses produce fewer side effects. [9]

Glucocorticosteroids are another viable first-line option, not a last resort. The UK's National Institute for Health and Care Excellence recommends a short course of oral glucocorticosteroids as one of the initial treatment options for an attack. If nonsteroidal anti-inflammatory drugs and colchicine are contraindicated, poorly tolerated, or ineffective, intra-articular or intramuscular glucocorticosteroids can be considered. [10]

In practice, this means a simple thing: the "right" anti-inflammatory drug for gout is chosen not by popularity, but by context. A young patient without serious comorbidities and an elderly patient with chronic kidney disease, hypertension, diabetes, and polypharmacy are two different clinical situations, and their anti-inflammatory tactics will differ. [11]

Table 2. Main groups of drugs for gout attacks

Group	Role	Strong point	Main limitations
Nonsteroidal anti-inflammatory drugs	First line	Rapid anti-inflammatory effect	Gastrointestinal, renal, cardiovascular risk
Colchicine	First line	Well suited for early initiation and for prophylaxis when starting urate-lowering therapy	Gastrointestinal side effects, drug interactions
Oral glucocorticosteroids	First line	Useful when nonsteroidal anti-inflammatory drugs are undesirable	Hyperglycemia, fluid retention, other steroid risks
Intra-articular or intramuscular glucocorticosteroids	An option in case of contraindications or ineffectiveness of other means	Useful for local inflammation or when oral administration is not possible	Require clinical assessment and appropriate conditions
Interleukin 1 inhibitors	Reserve	Option in difficult and resistant cases	Cost, infections, limited availability

Based on recommendations from the National Institute for Health and Care Excellence (NIH), the American College of Rheumatology and current reviews. [12]

How doctors choose a drug in practice

The first major filter is kidney function. In advanced chronic kidney disease, nonsteroidal anti-inflammatory drugs (NSAIDs) become a significantly less practical choice. A review of gout and kidney disease explicitly states that in advanced chronic kidney disease, these drugs are largely contraindicated due to nephrotoxicity, and published observations show an increased risk of acute kidney injury. [13]

The second filter is gastrointestinal risk. If a nonsteroidal anti-inflammatory drug is chosen, the UK's National Institute for Health and Care Excellence recommends considering the addition of a proton pump inhibitor. This is especially important in people with a history of peptic ulcer disease, gastrointestinal bleeding, advanced age, and concomitant medications that increase the risk of mucosal damage. [14]

The third filter is drug interactions and colchicine toxicity. Colchicine can be very beneficial, but this particular drug requires special care in people with impaired renal and hepatic function, as well as in those taking medications that affect its elimination. The current instructions from the United States Food and Drug Administration indicate that the combination of colchicine with inhibitors of the transport protein P-glycoprotein and the cytochrome P450 3A4 enzyme in patients with renal or hepatic impairment can lead to life-threatening and fatal toxicity. [15]

The fourth filter is the risk profile of glucocorticosteroids. For many patients, a short course is well tolerated, but if a person has poorly controlled diabetes, severe hypertension, severe infections, or other conditions that may be adversely affected by steroids, the choice must be made more carefully. This is why guidelines emphasize that the decision should take into account comorbidities and existing medications, not just the severity of pain. [16]

This is where it becomes clear why different patients are prescribed different medications despite seemingly identical diagnoses of gout. For a single inflamed joint in a person without severe comorbidities, the approach may be relatively simple. However, with multiple joint lesions, chronic kidney disease, anticoagulants, diabetes, or complex interactions, the choice requires more precise personalization, and sometimes consultation with a rheumatologist. [17]

Table 3. How an anti-inflammatory drug is usually chosen

Clinical situation	What is especially important to consider
Chronic kidney disease	Nonsteroidal anti-inflammatory drugs are often undesirable
High gastrointestinal risk	Caution is needed with nonsteroidal anti-inflammatory drugs, sometimes gastroprotection
Polypharmacy and risk of interactions	Colchicine requires special safety testing
Poor diabetes control	Glucocorticosteroids require caution
Inability to take orally or localized severe arthritis	Injectable steroid options may be considered.
Complex comorbidity	Often what is needed is individual choice, not a template scheme.

Based on guidelines and reviews on gout in patients with comorbidities.[18]

Colchicine and prevention of attacks during urate-lowering therapy

Gout is insidious because even properly initiated urate-lowering therapy can paradoxically trigger new attacks in the first few months. Therefore, anti-inflammatory drugs are used not only to treat an exacerbation that has already begun, but also to temporarily prevent attacks during the initiation or titration of uric acid-lowering therapy. This position is emphasized by both the American College of Rheumatology and the UK's National Institute for Health and Care Excellence. [19]

The American College of Rheumatology strongly recommends concomitant anti-inflammatory prophylaxis when initiating urate-lowering therapy for at least 3-6 months. Colchicine, nonsteroidal anti-inflammatory drugs, and prednisone or prednisolone are considered options. The practical purpose of such prophylaxis is simple: it allows the patient time to safely establish a long-term treatment regimen without derailment due to flare-ups triggered by therapy initiation. [20]

The UK National Institute for Health and Care Excellence (NIH) has colchicine as the most clearly supported prophylaxis option. In their evidence review, the committee noted that available data showed a reduction in attack frequency at 3 and 6 months with colchicine, so it was recommended as the primary prophylaxis option when initiating urate-lowering therapy. [21]

If colchicine is contraindicated, not tolerated, or ineffective, other anti-inflammatory approaches may be considered. The same review by the UK's National Institute for Health and Care Excellence states that nonsteroidal anti-inflammatory drugs or glucocorticosteroids may be used in cases of intolerance, contraindications, or ineffectiveness of colchicine. Here again, the principle of personalization based on comorbidity and risk factors comes into play. [22]

The dose of colchicine is also very important. Both the American College of Rheumatology and systematic reviews are moving away from older "aggressive" regimens, which involved repeating the drug until severe diarrhea was achieved. The current emphasis is on lower doses, as they offer a more favorable benefit-tolerability ratio. This applies both to the treatment of an attack and to the preventative approach when initiating urate-lowering therapy. [23]

Table 4. The role of anti-inflammatory drugs when initiating urate-lowering therapy

Question	Practical answer
Why is prevention necessary?	To reduce the risk of seizures in the first months of treatment
How long is it usually needed for?	Usually no less than 3-6 months
Which drug is most often considered first?	Often colchicine
What to do if you are intolerant to colchicine	Consider other options, taking into account the risks
Why low doses of colchicine are preferred	While similarly effective, they are usually better tolerated.

Based on the American College of Rheumatology guidelines, the UK National Institute for Health and Care Excellence review, and systematic reviews on colchicine.[24]

When standard medications are not suitable

Not all patients with gout attacks can be safely treated with first-line treatments. Sometimes, severe chronic kidney disease, a high risk of gastrointestinal bleeding, serious drug interactions, diabetes, the ineffectiveness of existing regimens, or poor tolerability of several classes of drugs simultaneously interfere. It is precisely for such situations that the concept of reserve anti-inflammatory therapy exists. [25]

The main reserve class today is interleukin 1 inhibitors. The European Alliance of Rheumatology Associations guidelines state that in patients with frequent attacks and contraindications to colchicine, nonsteroidal anti-inflammatory drugs and glucocorticosteroids, an interleukin 1 blocker can be considered. This is not a drug for routine use in the usual first attack, but an option for difficult, resistant or complicated cases. [26]

The most officially approved option in this group is canakinumab. Current U.S. Food and Drug Administration labeling states that it is used for the symptomatic treatment of gout attacks in adults for whom nonsteroidal anti-inflammatory drugs and colchicine are contraindicated, intolerable, or ineffective, and for whom repeated courses of glucocorticosteroids are unsuitable. This clearly places it not as a first-line treatment, but as a reserve for selected patients. [27]

However, salvage biological agents cannot be considered a "safe, easy alternative." The European Medicines Agency explicitly states that canakinumab should not be used in active infections, and also warns of the risk of serious infections and the undesirability of combining it with tumor necrosis factor inhibitors. Therefore, switching to salvage biological therapy typically means a narrower and more specialized management scenario. [28]

Interest in anakinra is growing. Systematic reviews and clinical trials in recent years suggest that it may be useful in patients with refractory attacks or comorbidities that limit the use of standard agents. However, in a number of countries and clinical systems, it remains an option used primarily by specialists, often outside the approved indication for gout. [29]

Table 5. When considering salvage therapy

Situation	What does this usually mean?
Neither colchicine, nor nonsteroidal anti-inflammatory drugs, nor glucocorticosteroids can be prescribed	A specialized assessment is needed
Frequent severe attacks against the background of multiple contraindications	Interleukin 1 blockade may be discussed.
Ineffectiveness of standard approaches	The diagnosis, severity of the disease and treatment plan need to be re-evaluated.
Active infection	Biological therapy may be contraindicated
Hospitalized complex patient	Often the participation of a rheumatologist and individual tactics are required.

Based on the European Alliance of Rheumatology guidelines, reviews and product labels. [30]

Main mistakes and practical conclusions

The most common mistake is trying to evaluate anti-inflammatory medications outside of an overall gout treatment plan. If a person experiences repeated attacks but only receives repeated courses of pain and inflammation medications, this usually indicates incomplete disease control. Current guidelines consider anti-inflammatory medications an important, but not the only, part of gout care. [31]

The second mistake is to assume that the higher the colchicine dose, the better the outcome. The current evidence base has shifted in the opposite direction: lower doses are preferable because they provide similar clinical benefits and fewer gastrointestinal complications. The old approach of increasing the dose until severe diarrhea occurs is no longer considered a reasonable standard approach. [32]

The third mistake is mechanically prescribing nonsteroidal anti-inflammatory drugs to everyone. In a young patient without a history of peptic ulcer, chronic kidney disease, or severe cardiovascular disease, they may be entirely appropriate. But in patients with advanced chronic kidney disease, high gastrointestinal risk, and complex comorbidities, such a tactic can do more harm than good. [33]

The fourth mistake is underestimating colchicine's drug interactions. For the clinician, this is one of the most sensitive medications for gout: it can be very beneficial, but requires careful consideration of concomitant therapy, especially in patients with impaired liver and kidney function. The official instructions explicitly describe life-threatening cases of toxicity with adverse combinations. [34]

The main practical conclusion is this: there is no single "best" anti-inflammatory drug for gout. There are three fully-fledged first-line groups—nonsteroidal anti-inflammatory drugs, colchicine, and glucocorticosteroids—and there are backup options for complex cases. The optimal choice always revolves around three questions: how quickly the inflammation needs to be reduced, what concomitant diseases are present, and whether it's time to simultaneously establish comprehensive long-term gout control. [35]

Table 6. The most important practical guidelines

A practical question	Short answer
What is the first thing prescribed during an attack?	Nonsteroidal anti-inflammatory drug, colchicine or glucocorticosteroid
Which drug is the "best"?	There is no universally better one
When Colchicine Is Particularly Beneficial	With proper patient selection and a low-dose approach
When Nonsteroidal Anti-Inflammatory Drugs Are a Poor Choice	In cases of severe chronic kidney disease and high gastrointestinal risk
When are backup options needed?	In case of contraindications, intolerance or ineffectiveness of standard therapy
Is it possible to treat only the attacks and not deal with the disease further?	This is usually a poor strategy for recurrent gout.

Based on current guidelines and reviews for the treatment of gout attacks.[36]

FAQ

What drug is best for relieving a gout attack?
There is no universal leader. Current guidelines consider nonsteroidal anti-inflammatory drugs, colchicine, and glucocorticosteroids as equal first-line options, with the choice based on comorbidities, drug interactions, and tolerability. [37]

Is colchicine better than nonsteroidal anti-inflammatory drugs (NSAIDs)?
Not necessarily. Available reviews suggest that low-dose colchicine can provide comparable clinical benefit, and the differences between it and NSAIDs in real-world practice are often determined not by the strength of the effect, but by the risk profile and convenience for the individual patient. [38]

Why are we talking about low-dose colchicine now?
Because the American College of Rheumatology and systematic reviews show that low doses are similarly effective and generally better tolerated than higher doses. The main benefit is reduced gastrointestinal side effects. [39]

Can steroids be used for gout?
Yes. A short course of oral glucocorticosteroid is one of the recommended first-line options, and intra-articular or intramuscular injections may be considered if other options are contraindicated, not tolerated, or have failed. [40]

When are nonsteroidal anti-inflammatory drugs (NSAIDs) particularly undesirable?
Primarily in patients with advanced chronic kidney disease and at high risk of gastrointestinal complications. The UK's National Institute for Health and Care Excellence (NIH) specifically recommends considering gastroprotection, and reviews on kidney disease highlight the nephrotoxic risk. [41]

Are anti-inflammatory drugs necessary if uric acid-lowering therapy has already been started?
Often, yes. When initiating or titrating urate-lowering therapy, the American College of Rheumatology recommends flare-up prophylaxis with anti-inflammatory drugs for at least 3-6 months, and the UK's National Institute for Health and Care Excellence particularly emphasizes the benefits of colchicine. [42]

When might biologic agents, such as canakinumab, be needed?
Only in selected, complex cases where first-line treatments are contraindicated, not tolerated, or do not produce a response, and repeated courses of glucocorticosteroids are not appropriate. This is not standard therapy for a typical attack, but a specialized reserve option. [43]

Key points from experts

John D. Fitzgerald, MD, PhD, MBA, is a professor of clinical medicine at the University of California, Los Angeles, and the lead author of the American College of Rheumatology's gout guidelines. His practical thesis for this topic can be summarized as follows: in gout, the key is not finding a "favorite" drug, but choosing the right first-line medication and developing a comprehensive disease management strategy. The fact that he led the development of the American College of Rheumatology guidelines makes his position one of the most significant for modern practice. [44]

Nicola Dalbeth, MD, FRCA, is Professor of Medicine at the University of Auckland and one of the world's leading gout researchers. The University of Auckland describes her as an academic rheumatologist who leads the gout clinical and laboratory research program, and her university publications underscore her international reputation in this field. Her key practical thesis for anti-inflammatory drugs is that gout is a disease with many myths and should be treated not ad hoc, but with an evidence-based strategy that combines acute attack relief and uric acid control. [45]

Naomi Schlesinger, MD, professor and chief of the Division of Rheumatology at the University of Utah Spencer Fox Eccles School of Medicine, is a renowned gout expert. The University of Utah directly calls her an authority on gout, citing her work in diagnosis, treatment, and understanding the mechanisms of the disease, as well as her expertise in canakinumab trials. Her practical thesis is well-suited for this article: complex gout should not be treated with routine medications alone, but reserve medications also require careful consideration and assessment of infection risks. [46]